Cempra Pharmaceuticals Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
45
- Latest Deal Type
-
M&A
Cempra Pharmaceuticals General Information
Description
Developer of clinical-stage pharmaceutical products intended to focus on medicines for curing bacterial infections. The company's clinical-stage pharmaceutical products are antibiotics used to treat multi-drug resistant bacterial infections, enabling patients avail advanced treatments targeting drug-resistant bacterial infections in the hospital and in the community.
Contact Information
Website
www.cempra.comCorporate Office
- 6320 Quadrangle Drive
- Chapel Hill, NC 27517
- United States
Corporate Office
- 6320 Quadrangle Drive
- Chapel Hill, NC 27517
- United States
Cempra Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 03-Nov-2017 | Completed | Profitable | |||
| 7. 2PO | 07-Jan-2016 | Completed | Profitable | |||
| 6. 2PO | 01-Jan-2015 | Completed | Profitable | |||
| 5. IPO | 03-Feb-2012 | Completed | Pre-Clinical Trials | |||
| 4. Debt - General | 01-Dec-2011 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 14-May-2009 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 14-Dec-2007 | $10M | $32.4M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 03-Oct-2006 | $22.4M | $22.4M | Completed | Product Development |
Cempra Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Cempra Pharmaceuticals Comparisons
Industry
Financing
Details
Cempra Pharmaceuticals Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| BioVersys | Venture Capital-Backed | Basel, Switzerland | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Achaogen | Formerly VC-backed | South San Francisco, CA | ||||
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria |
Cempra Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cempra Pharmaceuticals Patents
Cempra Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3055755-A1 | Compositions and methods for treating dry eye diseases | Inactive | 07-Mar-2017 | ||
| AU-2018230347-A1 | Compositions and methods for treating dry eye diseases | Inactive | 07-Mar-2017 | ||
| US-20210137961-A1 | Compositions and methods for treating dry eye diseases | Inactive | 07-Mar-2017 | ||
| EP-3592364-A1 | Compositions and methods for treating dry eye diseases | Inactive | 07-Mar-2017 | ||
| CA-3091413-A1 | Triazole-containing macrolides and ophthalmic uses therefor | Inactive | 17-Feb-2017 | A61K9/0048 |
Cempra Pharmaceuticals Executive Team (8)
| Name | Title | Board Seat |
|---|---|---|
| David Moore | Chief Commercial Officer & President | |
| David Zaccardelli | Board Member & Acting Chief Executive Officer |
Cempra Pharmaceuticals Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Gill | Self | Board Member | |
| David Zaccardelli | Self | Board Member & Acting Chief Executive Officer |
Cempra Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cempra Pharmaceuticals Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| BB Biotech | Asset Manager | Minority | ||
| Blackboard | PE-Backed Company | Minority | ||
| Devon Park Bioventures | Venture Capital | Minority | ||
| Hunt BioVentures | Venture Capital | Minority |
Cempra Pharmaceuticals FAQs
-
When was Cempra Pharmaceuticals founded?
Cempra Pharmaceuticals was founded in 2006.
-
Who is the founder of Cempra Pharmaceuticals?
Prabhavathi Fernandes Ph.D is the founder of Cempra Pharmaceuticals.
-
Who is the CEO of Cempra Pharmaceuticals?
David Zaccardelli is the CEO of Cempra Pharmaceuticals.
-
Where is Cempra Pharmaceuticals headquartered?
Cempra Pharmaceuticals is headquartered in Chapel Hill, NC.
-
What is the size of Cempra Pharmaceuticals?
Cempra Pharmaceuticals has 45 total employees.
-
What industry is Cempra Pharmaceuticals in?
Cempra Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Cempra Pharmaceuticals a private or public company?
Cempra Pharmaceuticals is a Private company.
-
What is Cempra Pharmaceuticals’s current revenue?
The current revenue for Cempra Pharmaceuticals is .
-
How much funding has Cempra Pharmaceuticals raised over time?
Cempra Pharmaceuticals has raised $397M.
-
Who are Cempra Pharmaceuticals’s investors?
Aisling Capital, BB Biotech, Blackboard, Devon Park Bioventures, and Hunt BioVentures are 5 of 9 investors who have invested in Cempra Pharmaceuticals.
-
Who are Cempra Pharmaceuticals’s competitors?
Pfizer Pakistan, BioVersys, Spero Therapeutics, Achaogen, and GlaxoSmithKline Consumer Nigeria are some of the 8 competitors of Cempra Pharmaceuticals.
-
When was Cempra Pharmaceuticals acquired?
Cempra Pharmaceuticals was acquired on 03-Nov-2017.
-
Who acquired Cempra Pharmaceuticals?
Cempra Pharmaceuticals was acquired by Melinta Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
